Mercado global de tratamento da demência corporal Lewy – Tendências do setor e previsão para 2031

Análise e tamanho do mercado de tratamento da demência corporal de Lewy

O mercado de tratamento da demência com corpos de Lewy (LBD) está a assistir a um crescimento significativo, impulsionado por vários fatores. A crescente prevalência da demência por corpos de Lewy, juntamente com o envelhecimento da população em todo o mundo, é um fator chave para o crescimento do mercado. Além disso, a crescente consciencialização sobre o DCL e os avanços nas técnicas de diagnóstico estão a levar à deteção e ao diagnóstico precoces, impulsionando a procura de opções de tratamento. O mercado é caracterizado por uma variedade de opções de tratamento, incluindo medicação, terapia e mudanças no estilo de vida. Medicamentos como os inibidores da colinesterase e os medicamentos para a doença de Parkinson são habitualmente utilizados para controlar os sintomas da DCL, como o défice cognitivo e as perturbações do movimento. Terapias como a fisioterapia , a terapia ocupacional e a terapia da fala podem ajudar a melhorar a qualidade de vida e a manter a função. As mudanças no estilo de vida, incluindo exercício regular e uma dieta saudável, também são importantes no controlo dos sintomas de DCL.

O tamanho global do mercado de tratamento da demência com corpos lewy foi avaliado em 5,66 mil milhões de dólares em 2023 e deverá atingir os 10,71 mil milhões de dólares até 2031, com um CAGR de 8,30% durante o período de previsão de 2024 a 2031. Para além dos insights sobre cenários de mercado como o valor de mercado, a taxa de crescimento, a segmentação, a cobertura geográfica e os grandes players, os relatórios de mercado com curadoria da Data Bridge Market Research incluem também análises especializadas aprofundadas, epidemiologia de doentes, análise de pipeline, análise de preços e enquadramento regulamentar.

Âmbito do relatório e segmentação de mercado       

Definição de mercado

A demência com corpos de Lewy (DCL) é uma perturbação neurológica progressiva que afeta o pensamento, a memória e o movimento. Embora não exista cura para o DCL, os tratamentos para a demência por corpos lewy centram-se no controlo dos sintomas e na melhoria da qualidade de vida. O tratamento envolve geralmente uma combinação de medicação, terapia e mudanças no estilo de vida.    

Dinâmica do mercado de tratamento da demência corporal de Lewy

Motoristas

• Crescente Sensibilização e Diagnóstico

Aumentar a consciencialização sobre a demência por corpos de Lewy (LBD) entre os profissionais de saúde e a população em geral é um fator crucial que impulsiona o crescimento do mercado. Com a crescente consciencialização, os profissionais de saúde estão mais inclinados a identificar sinais precoces de DCL, resultando num diagnóstico e intervenção atempados. O diagnóstico precoce permite o início atempado do tratamento e das estratégias de gestão, o que pode ajudar a melhorar a qualidade de vida dos indivíduos com DCL. Além disso, uma maior consciencialização da população em geral pode levar mais pessoas a procurar cuidados médicos para os sintomas relacionados com o DCL, contribuindo ainda mais para o diagnóstico e tratamento precoces. No geral, a crescente consciência do LBD está a desempenhar um papel significativo na condução do crescimento do mercado.       

• Avanços na investigação médica   

Os investigadores estão a explorar várias abordagens para a gestão do DCL, incluindo novos tratamentos farmacológicos, intervenções no estilo de vida e terapias não farmacológicas. Estes desenvolvimentos visam as causas profundas do LBD, como as acumulações anormais de proteínas no cérebro, para melhorar o controlo dos sintomas. Além disso, a investigação de biomarcadores para a DCL está a ajudar a melhorar a precisão do diagnóstico e a monitorizar a progressão da doença. Espera-se que o progresso contínuo na investigação médica conduza a tratamentos mais eficazes para o LBD, impulsionando o crescimento do mercado ao expandir o leque de opções disponíveis para os doentes e prestadores de cuidados de saúde.

Oportunidades

• Avanços Tecnológicos  

The field of Lewy body dementia (LBD) treatment has seen remarkable advancements in recent years, particularly in the development of diagnostic tools and treatment modalities. These technological innovations have greatly improved the accuracy of diagnosing LBD, allowing healthcare professionals to detect the disease at earlier stages. Advanced imaging techniques, such as positron emission tomography (PET) scans and magnetic resonance imaging (MRI), have enabled more precise visualization of brain structures and abnormalities associated with LBD. Furthermore, the application of biomarkers and genetic testing has enhanced diagnostic precision. In recent years, significant advancements have been made in the field of Lewy body dementia (LBD) treatment, particularly regarding the development of diagnostic tools and treatment modalities.       

• Increasing Aging Population 

As the population ages, the prevalence of LBD is expected to rise, leading to an increased demand for effective treatment options. The aging population is also more likely to experience other age-related health issues, such as Parkinson's disease and Alzheimer's disease, which are risk factors for developing LBD. This demographic shift has significant implications for healthcare systems worldwide, highlighting the need for innovative and accessible LBD treatments. The increasing aging population presents a substantial market opportunity for pharmaceutical companies and healthcare providers to develop and deliver effective treatments for LBD. The global aging population is a significant driver of the Lewy body dementia (LBD) treatment market.

Restraints/Challenges

• Side Effects of Medications  

Some medications commonly used to manage symptoms of LBD, such as antipsychotics and cholinesterase inhibitors, can cause side effects such as sedation, confusion, and movement disorders. These side effects can be particularly problematic for individuals with LBD, as they can exacerbate existing symptoms and impact the quality of life, due to which healthcare providers may be cautious in prescribing these medications, leading to limitations in their use.  One of the challenges in treating Lewy body dementia (LBD) is the potential for significant side effects from medications.            

• Lack of Disease-modifying Therapies

Unlike some other neurodegenerative diseases, such as Alzheimer's disease, there are currently no treatments that can slow or stop the progression of LBD. This is a major limitation in the management of the disease, as current treatments focus primarily on symptom management and do not address the underlying cause of LBD. The lack of disease-modifying therapies is another significant challenge in the treatment of LBD.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments

• In August 2023, a review of Phase II and III trials highlighted the emergence of new drugs for dementia with Lewy bodies (DLB). Despite DLB being associated with faster cognitive decline and having a greater negative impact on patients and caregivers compared to Alzheimer's disease (AD), drug development efforts for DLB lag behind those for AD. Currently, off-label drug options for DLB are limited to symptomatic agents developed for addressing cognitive deficits in AD, motor deficits in Parkinson's disease, or behavioral symptoms in psychiatric diseases. However, recent improvements in DLB diagnosis have sparked a new focus on the development of disease-modifying agents (DMA) for DLB
• In October 2022, Pfizer Inc., a multinational pharmaceutical and biotechnology corporation, completed the acquisition of Biohaven Pharmaceuticals Inc. for $11.6 billion. This strategic move is intended to bolster Pfizer's ability to provide innovative treatment solutions worldwide. Biohaven Pharmaceuticals Inc. is dedicated to developing pharmaceuticals for Parkinson's disease, a condition associated with Lewy body dementia, aligning with Pfizer's goal to expand its portfolio of therapies in this therapeutic area

Lewy Body Dementia Treatment Market Scope

The market is segmented on the basis of drug type, application type, mode of purchase, and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Drug Type

• Cholinesterase Inhibitors
• Antipsychotic Drugs
• Antidepressants
• Benzodiazepine
• Modafinil

Application Type

• Parkinson’s Disease
• Alzheimer’s Disease

Mode of Purchase

• Prescription
• Over the Counter

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacies
• Others

Lewy Body Dementia Treatment Market Regional Analysis/Insights

The market is analyzed and market size insights and trends are provided by country, drug type, application type, mode of purchase, and distribution channel as referenced above.

The countries covered in the market are U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa, Brazil, Argentina, and Rest of South America.

North America is expected to dominate the market due to factors such as a growing patient population with Lewy body dementia and Parkinson’s disease, an increase in the elderly population, high awareness among the population, and increased affordability of oral medications.

Asia-Pacific is expected to witness significant growth during the forecast period due to ongoing research and development efforts for the treatment of Lewy body dementia, untreated neurological conditions, and numerous opportunities in developing markets.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure Growth Installed Base and New Technology Penetration

The market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for lewy body dementia treatment market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the market. The data is available for historic period 2016-2021.

Competitive Landscape and Lewy Body Dementia Treatment Market Share Analysis

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points provided are only related to the companies' focus related to the market.

Some of the major players operating in the market are:

• Amneal Pharmaceuticals LLC. (U.S.)
• Boehringer Ingelheim International GmbH. (Germany)
• Merck & Co Inc. (U.S.)
• Abbott (U.S.)
• B Braun SE (Germany)
• Integra LifeSciences (U.S.)
• Johnson & Johnson Services, Inc. (India)
• Medtronic (Ireland)
• MicroPort Scientific Corporation (China)
• NuVasive, Inc (EUA)
• Orthofix USA LLC (EUA)
• Perrigo Company plc. (Irlanda)
• Stryker Corporation (EUA)
• Zimmer Biomet (EUA)
• Lily (EUA)
• F. Hoffmann-La Roche Ltd. (Suíça)
• Mylan NV (EUA)

SKU-61339